Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 4,938 Shares

Key Points

• CFO Oluyemi Okupe sold 4,938 Hims & Hers shares at an average price of $29.99, worth approximately $148,091, under a pre-arranged Rule 10b5-1 plan. He retained 264,117 shares after the transaction.
• The company reported strong quarterly revenue growth of 38.2% year over year to $753.21 million, exceeding estimates, but posted an adjusted loss of $0.37 per share versus the $0.05 consensus loss.
• HIMS faces continued regulatory and profitability concerns, including an FTC lawsuit, while analysts maintain a consensus “Hold” rating and a $32.43 price target.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 4,938 shares of the firm's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $29.99, for a total value of $148,090.62. Following the completion of the sale, the chief financial officer directly owned 264,117 shares in the company, valued at approximately $7,920,868.83. This represents a 1.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, June 18th, Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.09, for a total value of $1,943,389.47.
• On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.89, for a total value of $261,831.32.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.49, for a total value of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total value of $619,243.91.

Hims & Hers Health Stock Performance

NYSE HIMS traded up $0.86 during trading on Thursday, hitting $31.95. The company's stock had a trading volume of 18,871,045 shares, compared to its average volume of 26,241,924. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The firm has a 50 day moving average price of $32.17 and a 200 day moving average price of $26.05. The firm has a market cap of $7.45 billion, a P/E ratio of -50.71 and a beta of 2.40. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $65.30.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same quarter last year, the firm earned $0.17 earnings per share. The firm's quarterly revenue was up 38.2% compared to the same quarter last year. Equities research analysts forecast that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current fiscal year.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum rejected the FTC’s allegations concerning data privacy, advertising, billing and subscription cancellations, arguing that the agency misunderstands Hims & Hers’ business practices. His comments may be helping ease concerns after the recent regulatory-driven selloff. Hims & Hers rejects privacy allegations
• Positive Sentiment: Analysts remain focused on Hims & Hers’ growth potential, including margin expansion and broader access to care. A recent investment thesis characterized the current margin pressure as a potential buying opportunity, while the CEO said an AI health coach could launch within roughly 12 months and potentially improve medication adherence. Hims & Hers: Buying the Margin Dip
• Neutral Sentiment: Management’s planned expansion into AI-enabled care, testosterone and peptide treatments could create new growth avenues, but these initiatives remain prospective and do not immediately resolve regulatory or profitability concerns.
• Negative Sentiment: The FTC lawsuit remains the central overhang. It alleges improper handling of private health data and potentially deceptive billing and cancellation practices. Multiple law firms, including Kaplan Fox, Berger Montague and Kessler Topaz, have announced investigations that could increase legal costs, compliance requirements and potential securities-liability exposure. Kaplan Fox investigation
• Negative Sentiment: Recent earnings showed strong revenue growth of 38.2% year over year and revenue above expectations, but the company posted a substantially larger-than-expected loss. The $0.37 adjusted loss per share versus a $0.05 consensus loss highlights investor concerns about margins and execution.
• Negative Sentiment: Several executives reported stock dispositions, including sales by the CEO, CFO and CTO. Most were nondiscretionary share withholdings or sales under Rule 10b5-1 plans to cover taxes on vested equity, limiting their value as a confidence signal but still adding a modest supply-related overhang. SEC insider transaction filing

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of research reports. Needham & Company LLC increased their price target on shares of Hims & Hers Health from $35.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a research report on Friday, May 22nd. Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $25.00 to $26.00 and gave the stock a "hold" rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Hims & Hers Health in a research note on Friday, August 7th. Four analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $32.43.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. MassMutual Private Wealth & Trust FSB boosted its position in shares of Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock valued at $27,000 after acquiring an additional 319 shares in the last quarter. Sigma Planning Corp raised its position in Hims & Hers Health by 1.5% in the first quarter. Sigma Planning Corp now owns 26,007 shares of the company's stock worth $540,000 after purchasing an additional 388 shares in the last quarter. Captrust Financial Advisors raised its position in Hims & Hers Health by 3.1% in the second quarter. Captrust Financial Advisors now owns 14,612 shares of the company's stock worth $728,000 after purchasing an additional 443 shares in the last quarter. Binnacle Investments Inc bought a new position in Hims & Hers Health during the third quarter worth about $28,000. Finally, Northwestern Mutual Investment Management Company LLC lifted its stake in Hims & Hers Health by 1.1% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 46,607 shares of the company's stock worth $1,513,000 after purchasing an additional 521 shares during the period. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source